Milan and New York, 16/2/2021 – Healthware Group and Plexus Ventures have formed an alliance to structure deals for the pharmaceutical industry in the development and commercialization of DTx products. Given the increased attention and growth seen in the market, both companies are leveraging their expertise to become go-to partners for life sciences companies looking to incorporate DTx into their pipelines.
Plexus Ventures brings to the alliance over thirty years of experience and strategic knowledge of the pharma industry, long-established industry relationships, partnering experience and a time tested process to development and commercialization deals.
Healthware brings several decades of software app development and expertise as well as a history of digitally focused relationships with pharma. Healthware has also developed an investment fund to support and invest in digital health companies and nurtures a vast digital health network and expertise. In the area of digital therapeutics, Healthware Group supports both the research & development of DTx products as well as the go to market strategy of those products. This can be in partnership with pharma or supporting DTx companies in their growth.
One of the goals of the alliance is to educate pharma companies as to the value of digital therapeutics for their business model.
With regards to the alliance, Bob Moran, President at Plexus Ventures states,